Cannabis compound CBD stops coronavirus in test tube, but can it treat Covid?
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
MONDAY, MAY 23, 2022
MONDAY, MAY 23, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Cannabis compound CBD stops coronavirus in test tube, but can it treat Covid?

World+Biz

Reuters
25 January, 2022, 11:00 pm
Last modified: 25 January, 2022, 11:20 pm

Related News

  • What justifies China’s zero-Covid policy?
  • 22 Covid cases reported in 24hrs
  • China Junshi's potential Covid drug shows promise in small trial
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • N Korean leader slams officials' 'immaturity' in response to Covid outbreak

Cannabis compound CBD stops coronavirus in test tube, but can it treat Covid?

Reuters
25 January, 2022, 11:00 pm
Last modified: 25 January, 2022, 11:20 pm
Photo: Kimzy Nanney/Unsplash
Photo: Kimzy Nanney/Unsplash

Early research suggesting that a popular non-psychoactive compound derived from marijuana might help prevent or treat COVID-19 warrants further investigation in rigorous clinical trials, researchers say.

Several recent laboratory studies of cannabidiol, or CBD, have shown promising results, attracting media attention.

However, many other potential COVID treatments that showed promise in test tubes, from hydroxychloroquine to various drugs used to treat cancer and other diseases, ultimately failed to show benefit for COVID-19 patients once studied in clinical trials.

Marsha Rosner of the University of Chicago led a team that found CBD appeared to help curb SARS-CoV-2 in infected cells in laboratory experiments. "Our findings do not say this will work in patients. Our findings make a strong case for a clinical trial," she said.

Using small doses of highly purified CBD that approximate what patients receive in an oral drug already approved for severe epilepsy, Rosner and colleagues found that CBD did not keep the coronavirus from infecting cells in test tubes.

Rather, it acted soon after the virus entered the cells, blocking it from making copies of itself in part via effects on the inflammatory protein interferon. They found similar effects in infected mice, according to a report in Science Advances.

When they looked at a group of adults with severe epilepsy, the researchers found those who were taking the approved CBD drug had lower rates of COVID-19. But a backward look at a small number of patients does not yield conclusive information. Only randomized clinical trials can do that, Rosner said.

"I know my message is not something people want to hear," she said.

Small doses of tetrahydrocannabinol (THC) - the marijuana ingredient that causes the high - cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabichromene (CBC), and cannabigerol (CBG) did not keep the virus out of cells or prevent it from replicating, her team found.

"Not only did THC not work, but combining it with CBD prevented CBD from working," Rosner said.

NO COVID CURES AT CBD DISPENSARY

A separate team reported recently in the Journal of Natural Products that high doses of CBG and CBDA do prevent the coronavirus from breaking into cells.

Richard van Breemen from Oregon State University told Reuters that the doses his team tested were non-toxic to cells. It is not clear yet that similarly high doses would be safe for humans, his team said.

"You want the lowest possible effective dose," Rosner said, because of potential side effects as the drug is filtered through the liver.

The CBD her team tested was more than 98% pure, while purity in commercial products is far lower. "People should not run out and get CBD from their favorite dispensary," she said.

CBD products have become widely available in many forms and have been touted - often without proof from clinical trials - as treatments for pain and other ailments.

Small CBD trials in humans with COVID-19 are underway.

In one completed study, researchers in Brazil randomly assigned 105 patients with mild or moderate COVID-19 to receive CBD or a placebo for 14 days along with standard care. The CBD had no apparent effect, according to an October report in Cannabis and Cannabinoid Research.

In a proof-of-concept study at Sheba Medical Center in Israel, researchers are randomly assigning patients with mild COVID to receive CBD or a placebo.

An early-stage trial at Rabin Medical Center, also in Israel, aims to test the effect of CBD in severely or critically ill patients. However, study leader Dr. Moshe Yeshurun told Reuters that accruing participants has been difficult because the current Omicron-driven coronavirus wave "consists mostly of patients with mild to moderate disease."

Rosner's team is exploring the possibility of a clinical trial that would likely focus on asymptomatic or mild cases of COVID. Meanwhile, she is concerned that media reports overstating the potential of cannabinoids will lead people to self-medicate with CBD, stop using masks and avoid vaccines.

"We would love to be able to say specifically" that a certain dose of cannabinoids is helpful, she said, but at this point, "vaccine-induced antibodies and antibody drugs are much more effective at blocking infection."

Top News

Cannabis / Covid -19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Why we must resist geoeconomic fragmentation—and how
    Why we must resist geoeconomic fragmentation—and how
  • Trucks with palm oil fresh fruit bunches are parked in a queue at a palm oil factory in Siak regency, Riau province, Indonesia, April 26, 2022. Picture taken with a drone April 26, 2022. REUTERS/Willy Kurniawan
    Indonesia policy uncertainty hampers resumption of palm oil exports
  • Photo: Collected
    It's a rumour, no Monkeypox patient detected at BSMMU: VC

MOST VIEWED

  • Jewish visitors gesture as Israeli security forces secure the area at the compound that houses Al-Aqsa Mosque, known to Muslims as Noble Sanctuary and to Jews as Temple Mount, in Jerusalem's Old City, May 5, 2022. REUTERS/Ammar Awad/File Photo
    Senior Israeli lawmaker warns of "religious war" over Jerusalem moves
  • A hotel complex destroyed by a Russian missile during Russia's invasion of Ukraine is pictured in Odesa, Ukraine, on 8 May, 2022. REUTERS/Igor Tkachenko
    Ukraine says 87 were killed in Russian air strike last week
  • Five dead, scores trapped after building collapses in Iran
    Five dead, scores trapped after building collapses in Iran
  • Investcorp targets $400 million at Indian school infrastructure, warehousing
    Investcorp targets $400 million at Indian school infrastructure, warehousing
  • US President Joe Biden meets with India's Prime Minister Narendra Modi in the Oval Office at the White House in Washington, U.S., September 24, 2021. REUTERS/Evelyn Hockstein
    US considering $4B additional support for India
  • Picture: Reuters
    Russia's Putin jokes about being blamed for all the world's woes

Related News

  • What justifies China’s zero-Covid policy?
  • 22 Covid cases reported in 24hrs
  • China Junshi's potential Covid drug shows promise in small trial
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • N Korean leader slams officials' 'immaturity' in response to Covid outbreak

Features

Musk is denying the sexual harassment allegation that surfaced this week. Photo: Bloomberg

Elon Musk’s crazily banal week 

5h | Panorama
Asus Zenbook 14 Flip OLED: A touch of brilliance to your life

Asus Zenbook 14 Flip OLED: A touch of brilliance to your life

8h | Brands
Keep your phone by your side with this armband

Keep your phone by your side with this armband

6h | Brands
Are Focallure gel masks worth the hype?

Are Focallure gel masks worth the hype?

7h | Brands

More Videos from TBS

Why are Duranta TV shows popular?

Why are Duranta TV shows popular?

33m | Videos
Donbas is hell, says Zelenskiy

Donbas is hell, says Zelenskiy

1h | Videos
Threat of Monkeypox on the horizon

Threat of Monkeypox on the horizon

2h | Videos
Mosque of Mughal period in Gazipur

Mosque of Mughal period in Gazipur

2h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

3
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

4
Bangladesh at risk of losing ownership of Banglar Samriddhi
Bangladesh

Bangladesh at risk of losing ownership of Banglar Samriddhi

5
BSEC launches probe against Abul Khayer Hero and allies
Stocks

BSEC launches probe against Abul Khayer Hero and allies

6
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab